

Special Issue

Nano-Strategies in Fighting Cancer

Message from the Guest Editors

Over the past two decades, the field of nanotechnology has facilitated the emergence of the nano-bio interaction domain, enhancing our understanding of how nano-sized particles interact with the biological environment. Due to the small size of nanoparticles, they have the potential to interact with cytoskeleton components, thereby impacting cell functionality by altering mechanobiological responses. In this sense, the physicochemical properties of nanoparticles can be modified to potentially target cell mechanobiology, in addition to their other intended therapeutic purposes, for increased effectiveness. This precision allows for the control of critical functions, including migration, adhesion, and invasion, which are the key drivers of metastasis.

This Special Issue serves as a platform to showcase research papers and reviews that highlight recent developments in using nanoparticles to enhance cancer management. For instance, this includes targeting the biophysical properties of cancer cells for more effective treatment or improving cancer diagnosis through the development of sensitive and innovative methods.

Guest Editors

Dr. Ahmad Sohrabi Kashani

National Research Council of Canada, Montreal, QC, Canada

Prof. Dr. Muthukumaran Packirisamy

Department of Mechanical Engineering, Concordia University,
Montréal, QC H3G2W1, Canada

Deadline for manuscript submissions

closed (20 February 2025)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/187725

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)